IRIXIRIDEX Corporation

Despite a 7% revenue dip from retina headwinds, IRIDEX Corp (IRIX) posts record glaucoma probe volume and reaffirms full-year guidance.

Moby summary of IRIDEX Corporation's Q2 2026 earnings call

IRIDEX Corp (IRIX) reports a milestone in profitability and strategic partnerships amid international headwinds and supply chain challenges.

Moby summary of IRIDEX Corporation's Q1 2026 earnings call

Microsoft rides AI and Azure growth, but slowing cloud guidance, capacity limits, and rising competition cast a shadow on its momentum.

IRIX incurs narrower year-over-year loss per share in Q4 as growth in retina systems and glaucoma probes boosts revenues, though margins remain pressured by higher costs.

Moby summary of IRIDEX Corporation's Q4 2025 earnings call

Earlier today, IRIDEX Corporation released financial results for the quarter ended 01/03/2026. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact, including, but not limited to, statements concerning our strategic goals and priorities, product development matters, sales trends, and the markets in which we operate.

MOUNTAIN VIEW, Calif. AP) — Iridex Corp. IRIX) on Thursday reported a loss of $184,000 in its fourth quarter.